Tibco Introduces Spotfire Clinical to Improve Clinical Trials and Accelerate Drug Development
TIBCO Software Inc. announced the launch of TIBCO Spotfire® Clinical, providing an in-memory, analytics platform on the market that aims to allow clinical development teams to make faster and more accurate decisions. Through visual and interactive exploration of clinical data, Spotfire Clinical® will enable actionable decisions that enhance patient safety, streamline operations and accelerate time to market for new medications and devices.
Clinical development teams can visualize and interact with operational, clinical and safety data in a single interface to support forward-looking decisions. By leveraging the new integrated S+/R statistics and predictive analytics capabilities of the TIBCO Spotfire® Analytics Platform, users will be able to conduct advanced what-if scenarios and analysis to gain insights into data, without the intervention of IT resources or biostatisticians.
“We use TIBCO Spotfire software for analyzing and reviewing operational and medical data on all our clinical trials,” said John Keilty vice president of IT and Informatics, Infinity Pharmaceuticals. “With Spotfire, all our clinical, safety and operational data are available in real time. This enables us to shorten the time between critical development gates, and to meet key milestones sooner while simultaneously managing safety risk.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
